Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK

Published:2018-06-06 Issue:8 Volume:21 Page:810-820
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Johansson Erin Colleen¹,Hartz Susanne²,Kiri Sandeep Himatlal²,Kumar Gayathri²,Svedbom Axel¹

Affiliation:

1. Mapi Group, Stockholm, Sweden;

2. Eli Lilly and Company Ltd, United Kingdom

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1474747

Reference46 articles.

1. Psoriasis and its management

2. Psoriasis

3. Guidelines of care for the management of psoriasis and psoriatic arthritis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective;PLOS ONE;2024-09-06

2. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective;Dermatology and Therapy;2023-09-23

3. Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis;JAAD International;2021-12

4. Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain;Journal of Medical Economics;2021-01-01

5. Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions;PharmacoEconomics;2020-11-26